These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
35 related articles for article (PubMed ID: 27202812)
21. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. Ascher-Svanum H; Furiak NM; Lawson AH; Klein TM; Smolen LJ; Conley RR; Culler SD J Med Econ; 2012; 15(3):531-47. PubMed ID: 22304338 [TBL] [Abstract][Full Text] [Related]
22. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Haro JM; Suarez D; Novick D; Brown J; Usall J; Naber D; Eur Neuropsychopharmacol; 2007 Mar; 17(4):235-44. PubMed ID: 17137759 [TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary. Bitter I; Katona L; Zámbori J; Takács P; Fehér L; Diels J; Bacskai M; Lang Z; Gyáni G; Czobor P Eur Neuropsychopharmacol; 2013 Nov; 23(11):1383-90. PubMed ID: 23477752 [TBL] [Abstract][Full Text] [Related]
24. Comparative Effectiveness in Terms of Treatment Discontinuation of Orodispersable Versus. Standard Oral Olanzapine Tablets in Non-Adherent Patients: Results from a 1-Year European Outpatient Observational Study. Novick D; Montgomery W; Treuer T; Aguado J; Kraemer S; Haro JM Value Health; 2014 Nov; 17(7):A766. PubMed ID: 27202812 [No Abstract] [Full Text] [Related]
25. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008 [TBL] [Abstract][Full Text] [Related]
26. Overview of the findings from the European SOHO study. Suarez D; Haro JM Expert Rev Neurother; 2008 Jun; 8(6):873-80. PubMed ID: 18505352 [TBL] [Abstract][Full Text] [Related]
27. A milestone in house dust-mite-allergen immunotherapy: the new sublingual tablet S-524101 (actair). Bahceciler NN; Babayigit Hocaoglu A; Galip N Expert Rev Vaccines; 2014 Dec; 13(12):1427-38. PubMed ID: 25345538 [TBL] [Abstract][Full Text] [Related]